CAR Jurkat Cell Products

CAR Jurkat Cell Products

Genetic engineering of the immune system has shown great promise in the treatment of cancer, especially the use of chimeric antigen receptor (CAR)-T cells. Adoptive immunotherapy by using CD19-targeted CAR-T cells has had an acceptable potential for the treatment of chemotherapy-resistant and recurrent hematological malignancies, CAR molecular building is constructed by attaching an antigen recognition domain of antibodies to co-stimulatory and the zeta (ζ) signaling domains of T-cell receptor. CARs can redirect and activate T cells to the targeted tumor cells in an MHC-independent manner. Jurkat cells are an immortal human leukemic T cell line widely used to examine T cell activation and signaling mechanisms.

Here, Creative Biolabs presents a cost-efficient and rapid method for evaluating CARs in human Jurkat T cells. This advancement is anticipated to accelerate the discovery and improve the quality of candidate CAR-T cell therapies for future clinical applications. Specifically, Creative Biolabs has designed and developed a comprehensive list of second-generation CAR-modified Jurkat cell lines. These CAR-Jurkat T cells were functionally characterized in vitro. More specifically, the scFv-based second-generation CAR was efficiently expressed on the transfected Jurkat cells and could specifically activate the Jurkat cells after recognizing antigen on the cancer cells.

In addition to designing, cloning, and screening CAR-Jurkat cell products, we also support the characterization of CAR-Jurkat cells, including but not limit to: in vitro and in vivo analysis, sensitivity, and specificity, preclinical development, target-specific activation, anti-tumor activity, etc. Please do not hesitate to contact us to find a customized solution that suits your needs.

Please browse the target below to find the right product for you.

All services and products are only for lab research use, not for any clinical diagnosis or treatment.

Key Updates

Receive our latest news and insights.